Sakar Healthcare has received its second Marketing Authorization (MA) for an oncology injection in the European Union, marking another milestone in its global expansion. This newly approved product is intended for the treatment of colorectal cancer, a highly prevalent condition across Europe.
The approval was granted based on a dossier compiled under stringent EU regulatory guidelines, reinforcing the strength of Sakar’s research-led, EU GMP-certified oncology formulation facility. The company’s first oncology injection—approved in April 2025 for treating breast cancer, non-small cell lung cancer, and prostate cancer—is already progressing towards its first commercial supply.
With this second MA, Sakar can now commercially export its oncology injection products across EU markets. Several other products, including liquid and lyophilised injections as well as oral solids, are currently under review. Approvals for these are expected in the coming months, further accelerating Sakar’s presence in the European oncology segment.
